Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism – Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential alternative to...